Abstract:Heart failure is a complicated clinical syndrome, which has become one of the most prevalent causes of mortality globally [ 1 von Lueder T.G. Krum H. New medical therapies for heart failure. Nat. Rev. Cardiol. 2015; Crossref PubMed Scopus (39) Google Scholar , 2 Edelmann F. Epidemiology and prognosis of heart failure. Herz. 2015; 40: 176-184 Crossref PubMed Scopus (7) Google Scholar ]. A major risk factor for the development of heart failure is cardiac hypertrophy, which is the compensatory response of the heart to stress [ [3] Bisping E. Wakula P. Poteser M. Heinzel F.R. Targeting cardiac hypertrophy: toward a causal heart failure therapy. J. Cardiovasc. Pharmacol. 2014; 64: 293-305 Crossref PubMed Scopus (64) Google Scholar ]. Cardiac hypertrophy results from a complex signaling cascade which converges upon certain transcription factors and then activates nuclear cardiac fetal gene programs and ultimately leads to pathological cardiac hypertrophy [ [4] Kohli S. Ahuja S. Rani V. Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy. Curr. Cardiol. Rev. 2011; 7: 262-271 Crossref PubMed Scopus (52) Google Scholar ]. Among them, the Ca2+/calmodulin-dependent phosphatase calcineurin (CaN) is considered as a central prohypertrophic signaling effector. Activated CaN directly binds to and dephosphorylates its downstream the Nuclear Factor of Activated T cells (NFAT) in the cytoplasm, promoting its translocation to the nucleus where it participates in hypertrophic gene expression [ 5 Taigen T. De Windt L.J. Lim H.W. Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 1196-1201 Crossref PubMed Scopus (261) Google Scholar , 6 Walther S. Awad S. Lonchyna V.A. Blatter L.A. NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure. Am. J. Physiol. Heart Circ. Physiol. 2014; 306: H856-H866 Crossref PubMed Scopus (13) Google Scholar ]. Therefore, looking for the calcineurin inhibitors that attenuate cardiac hypertrophy might be of great diagnostic and therapeutic significance for heart failure patients.

Cucurbitacin B Protects Against Pressure Overload Induced Cardiac Hypertrophy.

Cucurbitacin-I Induces Hypertrophy in H9c2 Cardiomyoblasts Through Activation of Autophagy Via MEK/ERK1/2 Signaling Pathway

Cucurbitacin-I induces hypertrophy in H9c2 cardiomyoblasts through activation of autophagy via MEK/ERK1/2 signaling pathway.

Mechanism of cucurbitacin B underlying pressure overload-induced myocardial fibrosis

Thymoquinone Ameliorates Pressure Overload‐induced Cardiac Hypertrophy by Activating the AMPK Signalling Pathway

In Vitro and in Vivo Antitumor Activity of Cucurbitacin C, a Novel Natural Product from Cucumber

Cucurbitacin B Inhibits Proliferation, Induces G2/M Cycle Arrest and Autophagy Without Affecting Apoptosis but Enhances MTT Reduction in PC12 Cells

Cucurbitacin B Inhibits the Translational Expression of Hypoxia-Inducible Factor-1Α.

Carabin: Endogenous Calcineurin Inhibitor, a Potential Diagnostic and Therapeutic Target for Cardiac Hypertrophy in Heart Failure

Curcumin Prevents and Reverses Murine Cardiac Hypertrophy

Puerarin Attenuates Pressure Overload-Induced Cardiac Hypertrophy.

Arctiin Protects Against Cardiac Hypertrophy Through Inhibiting MAPKs and AKT Signaling Pathways.

Syringin Prevents Cardiac Hypertrophy Induced by Pressure Overload Through the Attenuation of Autophagy

Abstract P234: CTMP Negatively Regulates Pathological Cardiac Hypertrophy via Akt-dependent Manner

Andrographolide Protects against Aortic Banding-Induced Experimental Cardiac Hypertrophy by Inhibiting MAPKs Signaling

Carboxyl-Terminal Modulator Protein Ameliorates Pathological Cardiac Hypertrophy by Suppressing the Protein Kinase B Signaling Pathway.

SIRT1/IGFBPrP1/TGF Β1 Axis Involved in Cucurbitacin B Ameliorating Concanavalin A‐induced Mice Liver Fibrosis

Cryptotanshinone Attenuated Pathological Cardiac Remodeling In Vivo and In Vitro Experiments

Exogenous Cathepsin V Protein Protects Human Cardiomyocytes HCM from Angiotensin Ⅱ-Induced Hypertrophy.

Cordycepin Ameliorates Cardiac Hypertrophy Via Activating The Ampk Alpha Pathway

Progress in Antitumor Effect of Cucurbitacin B and Its Mechanism